Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
For Participants With Healthy Renal Function
Is in good health based on the opinion of the investigator.
Male participants agree to remain abstinent from heterosexual intercourse on a long-term basis or must agree to use contraception as instructed.
Female participants must be of nonchildbearing potential.
For Participants With end stage renal disease (ESRD)
With exception of the renal impairment, is in good health based on the opinion of the investigator.
Has ESRD maintained on stable regimen of at least 3 times per week hemodialysis (HD) for at least 3 months prior to the initial administration of the study intervention.
Male participants agree to remain abstinent from heterosexual intercourse on a long-term basis or must agree to use contraception as instructed.
Female participants must be of nonchildbearing potential.
You may not be if
For Participants With Healthy Renal Function
Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
Has a history of cancer (malignancy).
Is positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV).
Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
Has received any non-live vaccine starting from 14 days prior to study intervention or is scheduled to receive any non-live vaccine through 30 days following study intervention (except coronavirus disease 2019 \[COVID-19\]).
Participants With ESRD
Has a history of cancer (malignancy).
Has required frequent emergent HD (≥3) within a year prior to the initial dose of study intervention.
Is positive for HBsAg, hepatitis C antibodies, or HIV.
Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
Has received any non-live vaccine starting from 14 days prior to study intervention or is scheduled to receive any non-live vaccine through 30 days following study intervention (except COVID-19)
Clareo Health | A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)
